AX-2026-043380

Triptorelin · 5 mg declared · Chinese Peptide Company Co., Ltd. · lot CPC-2604-F3585

FAILVERIFIED

Report ID: AX-2026-043380
Compound: Triptorelin
Compound class: Hypothalamic and posterior-pituitary hormones
Supplier: CPC — Chinese Peptide Company Co., Ltd.
Batch / lot: CPC-2604-F3585
Declared label claim: 5mg
Laboratory: PeptideMeter
Assay date: 23 Jun 2026
Submitted: 02 Jul 2026
Quarter: 2026-Q2
Submitter: s.agyeman
Sample provenance: Supplier-supplied

Section 1

Results

Measured against the index acceptance specification for the hypothalamic and posterior-pituitary hormones class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 28 min gradient, 214 nm	97.86	% area	≥ 98.5	FAIL
Total impurities	RP-HPLC, sum of reported peaks	2.14	% area	≤ 1.5	FAIL
Largest single impurity	RP-HPLC — ring-opened pGlu (+18 Da)	1.05	% area	≤ 1.00	FAIL
Identity — theoretical monoisotopic mass	calculated from molecular formula	1310.6248	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	1310.6158	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-6.9	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	4.32	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.50	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.78	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.30	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.38	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 28 min gradient	9.10	min	9.12 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.10	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	58,602	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [L-Trp6]-diastereomer (gonadorelin analogue)	1.21	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 28 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 58,602, and skew follows the reported asymmetry factor of 1.10. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.05 % impurity against a 97.86 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Triptorelin — main peak	9.10	4,756,299	97.86	—
2	ring-opened pGlu (+18 Da)	8.65	51,033	1.05	+18.011
3	[L-Trp6]-diastereomer (gonadorelin analogue)	8.91	33,050	0.68	0.000
4	des-Gly10-NH2 (−74 Da)	8.86	13,123	0.27	-74.048
5	oxidised Trp (+16 Da)	8.78	6,804	0.14	+15.995
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 1310.6248 Da, computed from C64H82N18O13. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 1310.6158 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
3+	437.8822	437.8792	-0.0030	8.1
2+	656.3197	656.3152	-0.0045	57.8
1+	1311.6321	1311.6231	-0.0090	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.23	97.86	divergence +0.37 pp vs batch median
Total impurities (% area)	1.77	2.14
Largest single impurity (% area)	0.98	1.05
Water (%)	2.1	4.32
Counter-ion (%)	not stated	4.50
Peptide content (%w/w)	not stated	not determined
Endotoxin (EU/mg)	not stated	0.30
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 8 d) → assay. Submitter did not handle the vial.
Assay date: 23 Jun 2026
Submitted to the index: 02 Jul 2026
Laboratory: PeptideMeter, Tallinn, Estonia
Method basis: 28 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot CPC-2604-F3585 n=1

This is the only report on this lot. One report is not a batch characterisation.

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Triptorelin records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041562	QSC	QSC-2607-C6970	Janoshik	2026-Q3	99.92	2.82	89.6	Supplier-supplied	1	MARGINAL
AX-2026-043155	SSA	SSA-2601-Y7541	Kestrel	2026-Q2	99.28	5.11	103.9	Supplier-supplied	1	MARGINAL
AX-2026-043156	SSA	SSA-2601-Y7541	PeptideMeter	2026-Q2	99.20	4.53	—	Supplier-supplied	2	MARGINAL
AX-2025-020763	SGN	SGN-2504-A9926	Janoshik	2025-Q2	98.39	5.04	—	Buyer-sourced	0	FAIL
AX-2025-020765	SGN	SGN-2504-A9926	PeptideMeter	2025-Q2	98.28	4.54	106.3	Supplier-supplied	1	FAIL
AX-2025-020764	SGN	SGN-2504-A9926	VendorInvestigate	2025-Q2	98.01	4.92	97.8	Buyer-sourced	0	FAIL
AX-2025-020761	SGN	SGN-2504-A9926	Nordanalyt	2025-Q2	98.41	5.49	89.8	Supplier-supplied	1	FAIL
AX-2025-020762	SGN	SGN-2504-A9926	Janoshik	2025-Q2	98.52	4.72	106.0	Supplier-supplied	0	PASS

Other recent CPC records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043368	N-Acetyl Semax Amide	CPC-2602-D2941	Medutest	2026-Q3	98.79	6.05	102.1	Supplier-supplied	0	PASS
AX-2026-043335	Liraglutide	CPC-2602-G1978	Janoshik	2026-Q3	97.29	4.91	—	Laboratory-retained	1	FAIL
AX-2026-043283	L-Carnosine	CPC-2603-G1651	Medutest	2026-Q3	98.10	10.12	91.8	Supplier-supplied	1	FAIL
AX-2026-043365	BPC-157	CPC-2602-W2646	Medutest	2026-Q3	98.56	2.80	—	Supplier-supplied	1	MARGINAL
AX-2026-043332	Liraglutide	CPC-2602-G1978	Janoshik	2026-Q3	97.16	4.88	91.3	Supplier-supplied	1	FAIL
AX-2026-043289	L-Carnosine	CPC-2603-G1651	Janoshik	2026-Q3	98.01	10.52	—	Buyer-sourced	1	FAIL
AX-2026-043287	L-Carnosine	CPC-2603-G1651	Janoshik	2026-Q3	98.35	9.89	93.2	Supplier-supplied	2	FAIL
AX-2026-043367	N-Acetyl Semax Amide	CPC-2602-D2941	Nordanalyt	2026-Q3	99.39	6.16	92.4	Supplier-supplied	0	PASS